# ADARx Pharmaceuticals Inc. (ADRX) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $16.09, market value $1.8 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). ADARx Pharmaceuticals Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 516.6×**. Each dollar of revenue is priced at 516.6×, a level that requires very high margins or very fast growth to justify.
- **Free-cash-flow yield: 14.0%**. Free cash flow equals 14.0% of the market value. Above 5% is generally attractive.

## Profitability
- **Return on equity: 36.1%**. 36.1% on shareholders' equity is excellent if it is not driven by leverage; sustained above 20% usually signals a competitive advantage.
- **Return on invested capital: 10.3%**. Return on all capital, debt included, is 10.3%.
- **Return on assets: -14.4%**. Each dollar of assets produces -14.4% of profit.

## Growth
- **EPS growth (1 yr): -57.6%**. Earnings per share fell 57.6%.

## Financial health
- **Net debt / EBITDA: 5.5×**. It would take 5.5 years of operating earnings to repay net borrowings, above the 3× level most lenders treat as comfortable.
- **Current ratio: 16.18** (quick 16.18). Current assets cover the next year's liabilities 16.18 times.
- **Altman Z-score: 1.47**. A Z-score of 1.47 is in the distress zone, a signal to examine the balance sheet closely.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. ADARx Pharmaceuticals Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (4 analysts). 4 analysts cover ADARx Pharmaceuticals Inc.; the consensus is strong_buy, with an average price target of $34.25 (+113% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **From 52-week high: -30.7%** (7.3% above the low). Trading 31% below its 52-week high, deep in a drawdown.
- **RSI (14-day): 30**. An RSI of 30 is oversold; bounces are common, but oversold can stay oversold in a real decline.

Live score and charts: https://foliofundamentals.com/analyzer?s=ADRX · Page: https://foliofundamentals.com/stocks/adrx

Not investment advice.